首页> 外文会议>Cell culture engineering conference >NOVEL ENGINEERED CHO DG44 HOST CELL LINE DEMONSTRATES LOWERED UPR, INCREASED TITERS AND SUPERIOR QUALITY OF RECOMBINANT VACCINES
【24h】

NOVEL ENGINEERED CHO DG44 HOST CELL LINE DEMONSTRATES LOWERED UPR, INCREASED TITERS AND SUPERIOR QUALITY OF RECOMBINANT VACCINES

机译:新型工程化CHO DG44宿主细胞系证明了重组疫苗的低UPR,滴度增加和优异质量

获取原文

摘要

The Chinese Hamster Ovary (CHO) DG44 platform is routinely used at the Vaccine Production Program (VPP) for manufacturing Vaccine Research Center (VRC) pipeline therapeutic proteins. Clonal cell lines have been generated that express broadly neutralizing monoclonal antibodies (bNmAbs) against HIV-1 with titers ranging between 1 and 5 g/L. In the analysis of data from high and low productivity clones across a range of projects, high-producing clones were found to display increased viable cell density (VCD) and viability at later days in fed-batch culture. With an objective to understand the underlying mechanism for the observed differences in titer, we investigated the Unfolded Protein Response (UPR) pathway and found that multiple genes were differentially regulated among high- and low-producing clones. UPR-induced apoptosis was observed to be significantly higher in lower-producing clones and significantly lower in higher-producing clones at late days in culture. Our initial analysis emphasized a need to generate a platform host cell with lowered UPR and more efficient protein secretion capacity to achieve maximum yields. Through the course of developing and characterizing a panel of cell lines expressing varying levels of human furin for use in a trimeric viral antigen project, a CHO DG44 clone expressing low levels of human furin was identified that had high VCD and viability in later days of fed-batch culture. Reduced UPR at late days in these cells, particularly the lowered expression of apoptotic genes, was seen to correlate to the late day increases in VCD and viability. When the low furin expressing host CHO DG44 cells were used for recombinant protein expression, the increases in VCD and viabilities were maintained compared to platform CHO DG44 host and we achieved a 3 X increase in viral antigen titers without any change in the existing upstream process. It is our goal to characterize the quality of recombinant proteins expressed in DG44- furin engineered clones. The extent of unfolded protein response in viral antigen expressing clones, furin level, and the influence of these factors on the quality of protein is currently under investigation. Our work describes a successful effort to rationally develop a superior host cell for increased and efficient yield of difficult-to-synthesize recombinant targets and points to a potential path forward for generating higher-producing clones for bNmAbs as well.
机译:中国仓鼠卵巢(CHO)DG44平台通常在疫苗生产计划(VPP)中使用,用于生产疫苗研究中心(VRC)管道治疗蛋白。已经产生了表达抗HIV-1的广泛中和性单克隆抗体(bNmAb)的克隆细胞系,其滴度在1-5g / L之间。在对来自多个项目的高生产率和低生产率克隆的数据进行分析时,发现高产克隆在补料分批培养的后期显示出更高的存活细胞密度(VCD)和活力。为了了解所观察到的效价差异的潜在机制,我们研究了未折叠蛋白反应(UPR)途径,发现在高产和低产克隆中多个基因受到差异调节。在培养后期,观察到UPR诱导的凋亡在较低产量的克隆中显着较高,而在较高产量的克隆中显着较低。我们的初步分析强调需要生成具有降低的UPR和更有效的蛋白质分泌能力的平台宿主细胞,以实现最高产量。通过开发和表征一组表达不同水平的人类弗林蛋白酶的细胞系以用于三聚体病毒抗原计划,鉴定了表达低水平的人类弗林蛋白酶的CHO DG44克隆,在饲喂后期具有较高的VCD和活力分批培养。观察到这些细胞在后期的UPR降低,尤其是凋亡基因表达的降低,与VCD和生存力的后期升高相关。当将表达低弗林蛋白酶的宿主CHO DG44细胞用于重组蛋白表达时,与平台CHO DG44宿主相比,VCD和活力得以维持,并且病毒抗原的滴度增加了3倍,而现有上游过程没有任何变化。我们的目标是表征在DG44-弗林蛋白酶工程克隆中表达的重组蛋白的质量。目前正在研究病毒抗原表达克隆中未反应的蛋白质反应程度,弗林蛋白酶水平以及这些因素对蛋白质质量的影响。我们的工作描述了为合理开发出优质宿主细胞以提高难合成的重组靶标的效率而成功进行的努力,并指出了为产生更高产量的bNmAb克隆的潜在途径。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号